Abstract

Peroxiredoxin 6 (Prdx6) is a ubiquitously expressed antioxidant non-selenium glutathione peroxidase that is known to play a major role in various physiological and pathological processes. It belongs to the family of peroxidases (referred to as Peroxiredoxins, Prdx’s) that work independently of any prosthetic groups or co-factors, and instead utilize a peroxidatic thiol residue for peroxide reduction. Mammalian Prdx’s are classified according to the number of Cys implicated in their catalytic activity by the formation of either inter-molecular (typical 2-Cys, Prdx1–4) or intra-molecular (atypical 2-Cys, Prdx5) disulfide bond, or non-covalent interactions (1-Cys, Prdx6). The typical and atypical 2-Prdx’s have been identified to show decamer/dimer and monomer/dimer transition, respectively, upon oxidation of their peroxidatic cysteine. However, the alterations in the oligomeric status of Prdx6 as a function of peroxidatic thiol’s redox state are still ambiguous. While the crystal structure of recombinant human Prdx6 is resolved as a dimer, the solution structures are reported to have both monomers and dimers. In the present study, we have employed several spectroscopic and electrophoretic probes to discern the impact of change in the redox status of peroxidatic cysteine on conformation and oligomeric status of Prdx6. Our study indicates Prdx6′s peroxidase activity to be a redox-based conformation driven process which essentially involves monomer–dimer transition.

Highlights

  • The purified protein identity is verified via immunoblotting of dialysed desalted protein with anti-human Prdx[6] antibody (Fig. 1)

  • The reduced protein is generated via overnight incubation with excessive amount of DTT followed by its removal via dialysis

  • The purified protein that has not yet been exposed to either an oxidising or reducing agent was assumed to have cysteine group in sulfenic acid form (Cys-SOH) and not in thiol (Cys-SH), disulphide (Cys-S–S-Cys), sulfinic (Cys-SO2H) or sulfonic form (Cys-SO3H) because—(a) human Prdx[6] purified and crystallized under non-oxidising/non-reducing conditions are known to have a stable monooxidised peroxidatic c­ ysteine[7,11], (b) the distance of Cys 91 residue approximately 17 A° away from peroxidatic Cys prevents formation of an intra-molecular disulphide ­bond[11], (c) localization of Cys 47 at the bottom of a narrow pocket by the first turn of the helix α2 does not allow formation of intermolecular disulphide ­bond11,and (d) no external peroxide substrate is added which is essential for hyperoxidation of ­Prdx[65,29]

Read more

Summary

Methods

Trizma Base, EDTA, Sodium Hydroxide, Sodium dodecyl sulphate, Ethidium bromide, Imidazole, Tween-20, Tween-80, Sodium chloride, Potassium chloride, Glycerol, Acrylamide, bis-acrylamide, Ammonium persulphate, TEMED, Glycine, β-mercaptoethanol, Hydrogen peroxide ­(H2O2), Dithiothreitol (DTT), Horseradish peroxidase (HRP), 5,5′-dithiobis(2-nitrobenzoate) (DTNB), Bovine carbonic anhydrase, and Alpha-lactalbumin were purchased from Sigma Aldrich Pvt. Ltd. Luria Bertani Medium and Luria Bertani Agar (Difco), PBS tablets (Biobasic), Ni–NTA resin (Qiagen GmbH, Germany), DNA markers (GeneDireX Inc., USA), Precision dual colour Protein marker (Bio-Rad). Ampicillin and Kanamycin were purchased from MP Biomedicals. Primary (Monoclonal Anti-Prdx[6], clone 3A10-2A11 antibody produced in mouse, WH0009588M1) and secondary (Anti-mouse IgG (Fab Specific)-Peroxidase antibody produced in goat, A3682) to detect full length human Prdx[6] protein was procured from Sigma-Aldrich

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call